We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
XenoTech Adds In Vitro Toxicology to Its Drug Development Services
Product News

XenoTech Adds In Vitro Toxicology to Its Drug Development Services

XenoTech Adds In Vitro Toxicology to Its Drug Development Services
Product News

XenoTech Adds In Vitro Toxicology to Its Drug Development Services


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "XenoTech Adds In Vitro Toxicology to Its Drug Development Services"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The company is launching the ECVAM validated skin irritation screening assay (OECD TG 439) immediately, with additional screens for skin sensitization, ocular irritation and other organotypic models beginning this fall (2015) and future platforms expanding into endocrine disruption, genetox and hepatotoxicity.

XenoTech Tox Hex - Skin Irritation Assay.jpg
XenoTech has appointed Colleen Toole, Ph.D., as the Principal Scientist of its newly created in vitro toxicology group. Colleen will oversee all operations of the new department and will be instrumental in the continued development of XenoTech’s in vitro toxicology services.  Colleen has a strong knowledge of predictive in vitro toxicology models to identify new drug candidates, chemicals, cosmetics, and consumer products that present a low risk for toxicity.

“The formation of our new in vitro toxicology department shows XenoTech’s commitment to expanding into complementing areas around our extensive ADME - DMPK expertise to better predict in vivo outcomes through in vitro systems,” said XenoTech COO Jason Neat.

Advertisement